<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00760331</url>
  </required_header>
  <id_info>
    <org_study_id>I06026</org_study_id>
    <nct_id>NCT00760331</nct_id>
  </id_info>
  <brief_title>Long Term Follow up of a Cohort of Children With TCF2 Mutation:Evolution of Endocrine and Renal Function</brief_title>
  <acronym>TCF2</acronym>
  <official_title>A Long Term Follow up of a Cohort of Children With TCF2 Mutation:Evolution of Endocrine and Renal Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Limoges</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Anomalies of renal development are well know for patients treated for MODY-5 diabetes due to
      TCF2 mutation.A recent study confirms the existence of pediatric patients having TCF2
      mutation but presenting renal anomalies alone.Endocrine and renal evolution of these patients
      is unknown.The aim of this study is to follow a cohort of patients with TCF2 mutation and
      initially presenting renal anomalies alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Biologic analysis and renal ultrasonography once a year.

      After puberty or before kidney transplantation

        -  Abdominal and pelvic MRI

        -  Intravenous Glucose Tolerance Test
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Anticipated">July 2028</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hepatocyte Nuclear Factor 1-Beta</condition>
  <eligibility>
    <study_pop>
      <textblock>
        pediatric patients presenting an abnormality of kidney developmentdue to TCF2 mutation or
        deletion.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients presenting an anomaly of renal development due to TCF2 mutation

          -  Age&lt;18 years old

        Exclusion Criteria:

          -  Anomaly of renal development without TCF2 mutation

          -  Ageâ‰¥18 years old

          -  Parents or patients refusing to participate to the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent GUIGONIS, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Limoges</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vincent GUIGONIS, MD</last_name>
    <phone>0555056358</phone>
    <email>vincent.guigonis@chu-limoges.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vincent GUIGONIS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2008</study_first_submitted>
  <study_first_submitted_qc>September 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2008</study_first_posted>
  <last_update_submitted>September 25, 2008</last_update_submitted>
  <last_update_submitted_qc>September 25, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2008</last_update_posted>
  <responsible_party>
    <name_title>Norbert VIDAL</name_title>
    <organization>CHU de Limoges</organization>
  </responsible_party>
  <keyword>HNF1B</keyword>
  <keyword>TCF2</keyword>
  <keyword>MODY-5</keyword>
  <keyword>CAKUT</keyword>
  <keyword>Anomaly of renal development</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

